Roberts Zachary
EVP of R&D
Roberts Zachary has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Feb 4, 2026.
On the most recent filing, Roberts Zachary is listed as EVP of R&D at Allogene Therapeutics, Inc. Inside the rolling window, Roberts Zachary reported no open-market purchases and 2 open-market sales totaling $104K in ALLO. The largest disclosed transaction in the window is a sale of 35,700 ALLO shares on Feb 2, 2026, worth $63K.
Companies traded
Other insiders at ALLO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$104K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Roberts Zachary made?
Roberts Zachary has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Roberts Zachary trade?
Roberts Zachary has filed SEC Form 4 disclosures for 1 company, including ALLO.
When was Roberts Zachary's most recent SEC Form 4 filing?
Roberts Zachary's most recent SEC Form 4 filing on Tracefour is dated Feb 4, 2026.
What is Roberts Zachary's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Roberts Zachary is listed as EVP of R&D.
What is Roberts Zachary's total buy and sell value in the current window?
Inside the rolling retention window, Roberts Zachary bought $0 and sold $104K based on SEC Form 4 filings.
What was Roberts Zachary's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 35,700 ALLO shares on 2026-02-02, worth $63K, per SEC Form 4 filings.